Handelsbanken Fonder AB Increases Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Handelsbanken Fonder AB lifted its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 15.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 54,833 shares of the biopharmaceutical company’s stock after buying an additional 7,200 shares during the period. Handelsbanken Fonder AB’s holdings in ACADIA Pharmaceuticals were worth $1,006,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in ACAD. R Squared Ltd bought a new position in shares of ACADIA Pharmaceuticals in the 4th quarter worth approximately $47,000. Quest Partners LLC lifted its stake in shares of ACADIA Pharmaceuticals by 42.3% in the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 1,047 shares during the period. KBC Group NV lifted its stake in shares of ACADIA Pharmaceuticals by 67.0% in the 4th quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 2,044 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of ACADIA Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 1,066 shares during the period. Finally, PDT Partners LLC bought a new position in shares of ACADIA Pharmaceuticals in the 3rd quarter worth approximately $203,000. Institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Stock Up 1.8 %

NASDAQ ACAD opened at $19.34 on Friday. The company has a fifty day moving average of $18.37 and a two-hundred day moving average of $16.81. The firm has a market capitalization of $3.22 billion, a price-to-earnings ratio of 24.79 and a beta of 0.37. ACADIA Pharmaceuticals Inc. has a 52 week low of $14.15 and a 52 week high of $25.20.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Guggenheim cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $23.00 to $20.00 in a research note on Friday, January 3rd. Deutsche Bank Aktiengesellschaft assumed coverage on shares of ACADIA Pharmaceuticals in a research note on Tuesday, February 11th. They set a “hold” rating and a $22.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday. Needham & Company LLC restated a “buy” rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday. Finally, StockNews.com cut shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Eight equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.